PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of actamyolLink to Publisher's site
 
Acta Myol. 2008 December; 27(3): 90–97.
PMCID: PMC2858943

Candidate-gene testing for orphan limb-girdle muscular dystrophies

Summary

The term limb-girdle muscular dystrophies (LGMD) identify about two dozens of distinct genetic disorders. Additional genes must play a role, since there are LGMD families excluded from any known locus. The aim of our work is to test a number of candidate genes in unclassified LGMD patient and control DNA samples.

We selected the following 11 candidate genes: myozenin 1, 2 and 3), gamma-filamin, kinectin-1, enolase-3 beta, ZASP, TRIM 11 and TRIM 17, OZZ and zeta –sarcoglycan. These candidates were chosen for a combination of different reasons: chromosomal position, sequence homology, interaction properties or muscular dystrophy phenotypes in animal models.

The exon and flanking intron sequences were subjected to molecular testing by comparative mutation scanning by HT-DHPLC of LGMD patients versus control.

We identified a large number of variations in any of the genes in both patients and controls. Correlations with disease or possible modifying effects on the LGMD phenotype remain to be investigated.

Keywords: limb-girdle muscular dystrophies

Introduction

The Limb-Girdle Muscular Dystrophies (LGMD) are an important subgroup of muscular dystrophy, grouped together on the basis of common clinical features: they all primarily and predominantly affect proximal muscles of the scapular and the pelvic girdles. The clinical course is characterized by great variability, ranging from severe forms with rapid onset and progression to very mild forms allowing affected people to have fairly normal life spans and activity levels (1).

In addition, clinical characteristics such as hypertrophy of the calves, selectivity of muscle involvement and late stage cardiac complications are associated more or less specifically with each of the different forms (2). The molecular basis of the diseases is also highly heterogeneous (3).

LGMDs are divided into autosomal dominant (LGMD1) and autosomal recessive (LGMD2) forms with a lettering system denoting the chronology of locus identification (A to G for dominant and A to O for recessive LGMDs). Only 3 out of 7 autosomal dominant gene have been identified (46) whereas all but one of the causative genes have been identified for the 15 LGMD2 (721).

Despite several comprehensive studies developed over the last few years, there are at least 25% of families who are not linked to any known locus and 40% of isolated cases with a severe or intermediate LGMD phenotype with no mutation in any known gene.

The presence of many patients, both sporadic and familiar, not associated with any of the known LGMD loci has led us to explore new potential candidate genes for yet unassigned form of muscular dystrophies.

We screened a large cohort of LGMD patients, with a clear pathogenesis but without molecular diagnosis, by extensive mutation scanning in several candidate genes.

Materials and methods

DNA samples

Genomic DNA was extracted by phenol/chloroform to be used for DHPLC analysis. DNA was quantified and diluted at 20ng/µL for the amplification by PCR (22). We selected 180 DNA samples belonging to unassigned LGMD for which mutations in calpain 3 (LGMD2A), sarcoglycans (LGMD2C-2F), Telethonin (LGMD2G), TRIM32 (LGMD2H), FKRP (LGMD2I), POMT1 (LGMD2K), lamin A/C (LGMD1B) and caveolin 3 (LGMD1C) were excluded. Dysferlin (LGMD2B) and titin (LGMD2I) genes were also excluded by fluorescent microsatellite analysis. DNA samples were spotted into two 96-well plate, together with three empty wells and one control, then amplified and analyzed by DHPLC.

Polymerase Chain Reaction

The sequences of all candidate genes were downloaded from web interface Genome Browser Santa Cruz (http://genome.ucsc.edu/cgi-bin/hgGateway). All coding exons and intron-flanking regions were amplified by PCR from genomic DNA using primers pairs available on request. Primers were compared with results of the web-based program Primer3 (PRIMER3; primer3_www.cgi, v 0.2; http://frodo.wi.mit.edu). Each oligonucleotide was also checked by Blastn against the NCBI data bank genome for specificity (BLAST, www.ncbi.nlm.nih.gov/BLAST; NCBI, www.ncbi.nlm.nih.gov).

For PCR analysis, 60 ng of genomic DNA was amplified with a DNA Thermocycler System. An initial denaturation step at 95°C for 7 min was set, followed by 34 cycles (95°C for 30 s, 60–61°C for 1 min and 30 s, and 68°C for 1 min) followed by 95°C and a final extension at 68°C for 10 min.

DHPLC Analysis

We performed comparative mutation scanning to select amplicons for aberrant DHPLC profiles not shared by normal controls. Primers were longer than 25 nucleotides to reduce the allele preference determined by sequence differences located in the region of annealing. DHPLC was performed on a WAVE DNA fragment analysis system (Transgenomic Inc.) equipped with a DNASep column (3,500 High Throughput [HT]) employing a UV-C scanner to detect eluted DNA (23). Based on DHPLC requirements, special buffer formulations and primer design were used to improve sensitivity and specificity (22, 23).

Genomic DNA Sequence Analysis

Both strands were sequenced using BigDyes Terminator sequencing chemistry (Applied Biosystems). An ABI3130XL automatic DNA sequencer (Applied Biosystems) was used to analyze the product of the sequence reaction. We verified each nucleotide change by direct sequencing of a second amplified PCR product obtained with different primers. Mutations were numbered based on proteins and cDNA sequences in GenBank (Table (Table1).1). Nucleotides were numbered according to international recommendation (24).

Table 1
Genes and relative nucleotide and protein accession numbers.

Results

Selection of candidate genes

We have selected a pool of eleven candidate genes with different methodology: yeast-two hybrid and bioinformatics approach. It consists in selecting genes with a combination of interesting characteristics: muscle specific expression or localization (sarcomeric or sarcoplasmatic); function (known or hypothetic for muscle); structure (similarity with other LGMD proteins).

Myozenins (1, 2 and 3)

These three genes codify for three small Z-disk proteins which specifically binds calcineurin. Transgenic mice that overexpress the calcineurin develop a progressive cardiac hypertrophy, which causes stroke and death (25). Myozenin 1 is also known as FATZ for the interaction with three sarcomeric proteins: alpha-actinin, filamin C and telethonin. Gontier et al., in 2005 (26) observed the interaction of calsarcins with ZASP and myotilin, confirming the importance of the pathway in which they are involved.

Filamin C

The FLNC gene codify for the muscle-specific filamin isoform. It is involved in a form of autosomal dominant myofibrillar myopathy (MFM) described by Vorgerd et al. in 2005 (27). Patients presented with slow progressive skeletal-muscle weakness, beginning in the lower extremities, which is compatible with the clinical signs of LGMD.

ZASP

Z-band alternatively spliced PDZ-motif containing protein is a sarcomeric protein expressed in human cardiac and skeletal muscle at the Z-disk (28). Several mutations in ZASP gene have been identified as responsible for different dominant disorders: MFM and dilated cardiomyopathy (2931). The clinical phenotype in patients is heterogeneous, with variable age of onset, proximal or distal presentation and variable occurrence of cardiomyopathy.

Kinectin 1

It is a 160kDa transmembrane protein located on the cytoplasmic vesicles of the endoplasmic reticulum. This is probably present on the vesicles that operate the transport of proteins from the endoplasmic reticulum to the Golgi. It may mediate the binding between kinesin and vesicle membrane to be transported (32).

To date no disease has been linked to mutation in kinectin 1 gene.

Enolase 3-b

The enolase enzyme catalyze the conversion of 2-phosphoglycerate into 2-phosphoenolpyruvate, and the beta isoform is muscle specific.

In 2001, Comi et al. (33) described a patient with a metabolic myopathy showing myalgia, fatigue and stress-induced weakness. This patient resulted compound heterozygous for two missense mutations in ENO3 gene.

TRIM11 and TRIM17

These are two small cytosolic proteins belonging to tripartite motif containing protein family (TRIM) as the muscular dystrophy 2H gene TRIM32. The two genes map at chromosome 1 in the critical region for the congenital muscular dystrophy 1B (MDC1B, OMIM #604801). The disease is characterized by proximal muscle weakness with hypertrophy, respiratory failure and increased CK serum levels.

ζ-sarcoglycan

It is a well known gene whose protein product belongs to sarcoglycans protein family (34). It has been demonstrated its ability to form an alternative complex with α, β and δ in different tissues if γ-sarcoglycan is absent.

Four sarcoglycans gene are mutated in LGMDs (α, β, γ and δ) and ε- is the gene mutated in the myoclonic dystonic syndrome (DYT11, 35).

OZZ

It is a small muscle specific protein and is a member of SOCS proteins family. In 2004, Nastasi et al. demonstrated the involvement of OZZ in an active E3-ligase complex in which β-catenin serves as substrate in vivo. OZZ knock-out mice show a muscle phenotype with an increased nuclei centralization and misalignment of myofibrils (36).

Mutation scanning

We analyzed all coding exons and flanking introns and verified whether each variation was present in DB-SNP (NCBI) or not. We excluded those described and only listed new gene variants. We identified 79 heterozygous variations classified as:

1. 34 intron changes;

2. 23 silent changes, without aminoacid substitution;

3. 22 missense variations.

We checked the presence of the 22 missense variations in 200 non affected individuals of the same genetic origin. Sixteen variations were not present in normal controls. For most cases conserved aminoacid are changed. Tables Tables22 below describe all variations identified in our screening gene by gene.

Table 2
Myozenins.

Discussion

Isolated cases of patients affected by rare genetic disorders are not amenable to studies of their Mendelian causes. The genetic nature of the condition can be nevertheless attributed, when there is a precise knowledge of the disease gene(s): There are, however, two main obstacles: genetic heterogeneity and incomplete penetrance. LGMD suffer from both problems, since the heterogeneity seems very complex with a dozen of major genes that explain up to 50-60% of cases and, hypothetically, hundreds of other genes involved in the remaining 40%. In addition, there are cases of causative mutations that are not associated with disease.

We selected 11 genes and performed mutation analysis. Each missense variation was then counted in a comparable number of matched controls. We analyzed two plates containing 180 DNA samples for which no mutation was previously found. All heterozygous variations were found in sporadic patients and no segregation analysis could be performed in their families. Thus, the variations we identified cannot be considered as responsible for recessive LGMD phenotype and we can conclude that none of the selected genes can be considered a common cause of recessive LGMD.

Recently, mutations in both ZASP (31) and filamin C (27) have been associated with myofibrillar myopathy with dominant inheritance. Only missense and one nonsense mutations have been identified. We cannot exclude that the variations we identified in these two genes could be responsible for the observed phenotype, since no histological data are available for those patients.

The presence of novel 16 missense variations that were absent in controls can be intriguing on the basis of general considerations about possible modifier variations (37). In particular in Kinectin-1 (32) we identified seven missense alleles in LGMD that were not shared by healthy controls. Larger population studies are required to assess this point.

Table 3
Filamin C FLNC.
Table 4
ZASP.
Table 5
Kinectin-1 KTN1.
Table 6
Enolase 3 beta, TRIM and SCGZ.

Acknowledgments

We are particularly grateful to Luisa Politano and partly EuroBioBank for support in providing us DNA samples. In addition, we thank Enzo Ricci, Carlo Minetti, Marina Fanin, Alessandra Ferlini, Haluk Topaloglu, and many others for DNA samples. This study was supported by grants from Telethon (TIGEM-TNP42TELC), Ministero dell’Istruzione dell’Università e della Ricerca (MIUR: PRIN 2006).

References

1. Nigro V. Molecular bases of autosomal recessive limb-girdle muscular dystrophies. Acta Myol 2003;22:35-42. [PubMed]
2. Danièle N, Richard I, Bartoli M. Ins and outs of therapy in limb girdle muscular dystrophies. Int J Biochem Cell Biol 2007;39:1608-24. [PubMed]
3. Guglieri M, Bushby K. How to go about diagnosing and managing the limb-girdle muscular dystrophies. Neurol India 2008;56:271-80. [PubMed]
4. Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 2000;9:2141-7. [PubMed]
5. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999;21:285-288. [PubMed]
6. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998;18:365-8. [PubMed]
7. Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995;81:27-40. [PubMed]
8. Bashir R, Britton S, Stratchan T, et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nature Genet 1998;20:37-42. [PubMed]
9. Noguchi S, McNally EM, Ben Othmane K, et al. Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science 1995;270:819-22. [PubMed]
10. Roberds SL, Leturcq F, Allamand V, et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 1994;78:625-33. [PubMed]
11. Bönnemann CG, Modi R, Noguchi S, et al. Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nature Genet 1995;11:266-73. [PubMed]
12. Nigro V, de Sa Moreira E, Piluso G, et al. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nature Genet 1996;14:195-8. [PubMed]
13. de Sa Moreira E, Wiltshire TJ, Faulkner G, et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nature Genet 2000;24:163-6. [PubMed]
14. Frosk P, Weiler T, Nylen E, et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet 2002;70:663-72. [PubMed]
15. Brockington M, Yuva Y, Prandini P, et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001;10:2851-9. [PubMed]
16. Hackman P, Vihola A, Haravuori H, et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet 2002;71:492-500. [PubMed]
17. Balci B, Uyanik G, Dincer P, et al. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord. 2005;15:271-5. [PubMed]
18. Godfrey C, Escolar D, Brockington M, et al. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol 2006;60:603-10. [PubMed]
19. Clement E, Mercuri E, Godfrey C, et al. Brain involvement in muscular dystrophies with defective dystroglycan glycosylation. Ann Neurol 2008;64:573-82. [PubMed]
20. Biancheri R, Falace A, Tessa A, et al. POMT2 gene mutation in limb-girdle muscular dystrophy with inflammatory changes. Biochem Biophys Res Commun 2007;363:1033-7. [PubMed]
21. Jarry J, Rioux MF, Bolduc V, et al. A novel autosomal recessive limb-girdle muscular dystrophy with quadriceps atrophy maps to 11p13-p12. Brain. 2007;130:368-80. [PubMed]
22. Underhill PA, Jin L, Lin AA, et al. Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. Genome Res 1997;7:996-1005. [PubMed]
23. O’Donovan MC, Oefner PJ, Roberts SC, et al. Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. Genomics. 1998;52:44-9. [PubMed]
24. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001;109:121-4. [PubMed]
25. Frey N, Richardson JA, Olson E. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc Natl Acad Sci USA 2000;97:14632-7. [PubMed]
26. Gontier Y, Taivainen A, Fontao L, et al. The Z-disc proteins myotilin and FATZ-1 interact with each other and are connected to the sarcolemma via muscle-specific filamins. J Cell Sci 2005;118:3739-49. [PubMed]
27. Vorgerd M, van der Ven PF, Bruchertseifer V, et al. A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. Am J Hum Genet 2005;77:297-304. [PubMed]
28. Griggs R, Vihola A, Hackman P, et al. Zaspopathy in a large classic late-onset distal myopathy family. Brain 2007;130:1477-84. [PubMed]
29. Vatta M, Mohapatra B, Jimenez S, et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 2003;42:2014-27. [PubMed]
30. Arimura T, Hayashi T, Terada H, et al. A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C. J Biol Chem 2004;279:6746-52. [PubMed]
31. Selcen D, Engel AG. Mutations in ZASP define a novel form of muscular dystrophy in humans. Ann Neurol 2005;57:269-76. [PubMed]
32. Abe E, Okawa S, Sugawara M, et al. Identification of ER membrane targeting signal of kinectin. Neurosci Lett 2007;413:238-40. [PubMed]
33. Comi GP, Fortunato F, Lucchiari S, et al. Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann Neurol 2001;50:202-7. [PubMed]
34. Wheeler MT, Zarnegar S, McNally EM. Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Hum Mol Genet 2002;11:2147-54. [PubMed]
35. Asmus F, Zimprich A, Tezenas Du Montcel S, et al. Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002;52:489-92. [PubMed]
36. Nastasi T, Bongiovanni A, Campos Y, et al. Ozz-E3, a muscle-specific ubiquitin ligase, regulates beta-catenin degradation during myogenesis. Dev Cell 2004;6:269-82. [PubMed]
37. Heydemann A, Doherty KR, McNally EM. Genetic modifiers of muscular dystrophy: implications for therapy. Biochim Biophys Acta. 2007;1772:216-28. [PubMed]

Articles from Acta Myologica are provided here courtesy of Pacini Editore